Listerine toothpaste six-month clinical trial necessary for gingivitis claims -- FDA cmte.
This article was originally published in The Tan Sheet
Executive Summary
WARNER-LAMBERT LISTERINE ANTIPLAQUE/ANTIGINGIVITIS TOOTHPASTE approval would require a six-month clinical trial, FDA's Dental Plaque Subcommittee concluded following a Warner- Lambert presentation of a proposed testing protocol at its meeting in Gaithersburg, Md. May 27. The advisory group recommended that one additional clinical trial would be sufficient to establish the ingredient combination's safety and efficacy in the new dosage form. The Nonprescription Drugs Advisory Committee subgroup based its opinion on its prior determination that Listerine Antiseptic mouthwash's combination of essential oils - menthol, thymol, methyl salicylate and eucalyptol - is a safe and effective antiplaque and antigingivitis agent in concentrations of 51.7 mg/dose ("The Tan Sheet" Nov. 3, 1997, p. 4).
You may also be interested in...
W-L Listerine Anticaries Fluoride Rinse Formula Change Proposed To FDA
Warner-Lambert has changed its proposed fluoride-containing oral anticaries/antiplaque/antigingivitis rinse to a .02% sodium fluoride formula to reflect results from recently conducted market research on taste, the company says in comments submitted to FDA May 15.
W-L Listerine Anticaries Fluoride Rinse Formula Change Proposed To FDA
Warner-Lambert has changed its proposed fluoride-containing oral anticaries/antiplaque/antigingivitis rinse to a .02% sodium fluoride formula to reflect results from recently conducted market research on taste, the company says in comments submitted to FDA May 15.
W-L Listerine Anticaries Fluoride Rinse Formula Change Proposed To FDA
Warner-Lambert has changed its proposed fluoride-containing oral anticaries/antiplaque/antigingivitis rinse to a .02% sodium fluoride formula to reflect results from recently conducted market research on taste, the company says in comments submitted to FDA May 15.